PRÉNUMBRA Trademark

Trademark Overview


On Tuesday, August 11, 2020, a trademark application was filed for PRÉNUMBRA with the United States Patent and Trademark Office. The USPTO has given the PRÉNUMBRA trademark a serial number of 79295828. The federal status of this trademark filing is REGISTERED as of Tuesday, October 5, 2021. This trademark is owned by Clinuvel (UK) Ltd. The PRÉNUMBRA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceuticals; Pharmaceutical drugs for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of...
prÉnumbra

General Information


Serial Number79295828
Word MarkPRÉNUMBRA
Filing DateTuesday, August 11, 2020
Status700 - REGISTERED
Status DateTuesday, October 5, 2021
Registration Number6504560
Registration DateTuesday, October 5, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 20, 2021

Trademark Statements


Goods and ServicesPharmaceuticals for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceuticals; Pharmaceutical drugs for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical drugs; Pharmaceutical preparations for the prevention and treatment of autoimmune, inflammatory and skin diseases or disorders, for the treatment of viral, metabolic, endocrine, musculoskeletal, ophthalmic, cardiovascular, cerebrovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders, for the treatment of vascular anomalies and oedema and for the prevention and treatment of genetic diseases and disorders; hemodynamic, vasoactive and anti-oncotic pharmaceutical preparations; Pharmaceuticals used for cerebrovascular accidents in the nature of strokes; Cardiovascular drug preparations; Cardiovascular pharmaceuticals; cardiovascular pharmaceutical preparations; Cardiovascular medicinal agents for medical purposes; Cardiovascular drugs used in treating shocks; cardiovascular drugs used in myocardial infarctions; cardiovascular drugs used in treating arrhythmias; cardiovascular drugs used in angina pectoris; pharmaceutical preparations for the treatment of cardiovascular disease; cardiovascular drugs used in treating congestive heart failure (CHF); Pharmaceutical preparations, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide for use in treating skin and skin relating conditions and disorders; Medicated sun tanning preparations for pharmaceutical purposes, preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Pharmaceutical preparations for skin care; pharmaceutical preparations for treating skin disorders; Medicated dermatological preparations; Dermatological pharmaceutical substances; Dermatological pharmaceutical products, namely, preparations for treating or preventing skin disorders; Medicinal creams for the protection of the skin; Medicated skin care creams for medical use for treating or preventing skin disorders; Medicated skin care preparations for medical use; Medicated skin creams and lotions; medicated creams for application after exposure to the sun; pharmaceutical skin lotions; preparations for cleansing the skin for medical use; Chemical and biological preparations, substances, reagents and compounds for the delivery and storage of a wide range of pharmaceuticals which are preferably based on analogues of melanocyte stimulating hormone (MSH), in particular afamelanotide; Afamelanotide hormone in aqueous and gel formulations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 19, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameClinuvel (UK) Ltd
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameClinuvel (UK) Ltd
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameClinuvel (UK) Ltd
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Monday, April 18, 2022FINAL DECISION TRANSACTION PROCESSED BY IB
Thursday, March 24, 2022FINAL DISPOSITION NOTICE SENT TO IB
Thursday, March 24, 2022FINAL DISPOSITION PROCESSED
Wednesday, January 5, 2022FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, October 5, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, July 20, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 20, 2021PUBLISHED FOR OPPOSITION
Monday, July 19, 2021NOTIFICATION PROCESSED BY IB
Wednesday, June 30, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, June 30, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, June 30, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, June 17, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 16, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 16, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 16, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, January 11, 2021REFUSAL PROCESSED BY IB
Monday, December 21, 2020NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, December 21, 2020REFUSAL PROCESSED BY MPU
Monday, December 14, 2020NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sunday, December 13, 2020NON-FINAL ACTION WRITTEN
Sunday, December 6, 2020ASSIGNED TO EXAMINER
Friday, October 23, 2020APPLICATION FILING RECEIPT MAILED
Monday, October 19, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, October 15, 2020SN ASSIGNED FOR SECT 66A APPL FROM IB